Fast sepsis test can save lives

December 22, 2010

Although it is the third most frequent cause of death in Germany, blood poisoning is frequently underestimated. In this country, 60,000 persons die every year from some form of sepsis, almost as many as from heart attacks. The Sepsis Nexus of Expertise states that patients arriving at the intensive care ward with blood poisoning only have a 50% chance of surviving. One of the reasons for the high mortality rate is the fact that patients are not correctly treated due to late diagnosis. The doctor and the patient used to have to wait as much as 48 hours for the laboratory analysis.

In future, a new mobile diagnostics platform will be guaranteeing fast and low-cost infection diagnostics even while the patient is being transported to the hospital. It's called MinoLab and it consists of a plastic card the size of a credit card that is inserted in an analysis unit that is smaller than a notebook. This system provides findings in less than one hour to enable the doctor to prescribe the life-saving therapy. This is based on magnetic particles that dock onto the cells to be studied in a blood sample and run through the system fully automatically with magnetic force. At the end of the process, the diagnosis is made with magnetic sensors. MinoLab is presently being developed in a project of the German Federal Ministry of Education and Research by the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig, Germany in collaboration with Magna Diagnostics, a company hived off from the Fraunhofer Society. Other project partners are the Fraunhofer Institute for Reliability and Microintegration (IZM) in Berlin as well as the companies Siemens, Dice, microfluidic Chip Shop and the Austrian Institute of Technology.

Dr. Dirk Kuhlmeier, a scientist at the Fraunhofer Institute for Cell Therapy and Immunology, explains how all that works: "After taking a sample of blood, magnetic nanoparticles bind themselves to the target cells in the blood sample through specific catcher molecules. We then use a simple magnet to transfer the particles onto the plastic card along with the pathogens and move them through various miniaturized reaction chambers which is where the polymerase chain reaction takes place. This is a method for copying even the smallest DNA sequences of pathogens millions of times. After it is copied, the nanoparticles transport the pathogen DNA into the detection chamber where a new type of magnetoresistive biochip can identify pathogens and antibiotics resistances." Our researcher goes on: "All reactions starting from sample preparation through isolating the target molecules right down to documentation are carried out without any contact and fully automatically." This means that routine operation is made much simpler for the laboratory technician and it reduces the risk of contamination from bacteria introduced from the environment that set off false alarms. But there is another benefit, as Dr. Kuhlmeier explains: "We not only save time with the combination of magnetic nanoparticles in a new type of micro-fluid. Miniaturization means we also save expensive apparatuses."

The experts have already been successful at using magnetic nanoparticles to isolate and document the sepsis pathogens, although Kuhlmeier says, "it will be another two years or so until we are able to produce a prototype of the diagnostic platform." Platform technology is not only suited for sepsis tests. It will be able to back up doctors in hospitals and private practices answering a wide range of molecular biological issues ranging from genetic predisposition right down to cancer diagnostics.
-end-


Fraunhofer-Gesellschaft

Related Sepsis Articles from Brightsurf:

Hormone involved in obesity is a risk factor for sepsis
A group of scientists from Instituto Gulbenkian de Ciência (IGC), led by Luís Moita, discovered that a hormone that has been pointed out as a treatment for obesity reduces the resistance to infection caused by bacteria and is a risk factor for sepsis.

Antihypotensive agent disrupts the immune system in sepsis
Patients who go into shock caused by sepsis (septic shock) are treated with the antihypotensive agent norepinephrine.

Milestone for the early detection of sepsis
Researchers from Graz, Austria, are developing a ground-breaking method that uses biomarkers to detect sepsis 2 to 3 days before the first clinical symptoms appear.

Breast milk may help prevent sepsis in preemies
Researchers at Washington University School of Medicine in St. Louis and Mayo Clinic in Rochester, Minn., have found -- in newborn mice -- that a component of breast milk may help protect premature babies from developing life-threatening sepsis.

Finding a new way to fight late-stage sepsis
Researchers have developed a way to prop up a struggling immune system to enable its fight against sepsis, a deadly condition resulting from the body's extreme reaction to infection.

Study: Sepsis survivors require follow-up support
Survivors of sepsis -- a life-threatening response to an infection -- have expressed a need for advocacy and follow-up support, according to a study authored by professors at the University of Tennessee, Knoxville, and the University of Tennessee Health Science Center in Memphis, and published in Dimensions of Critical Care Nursing.

After decades of little progress, researchers may be catching up to sepsis
After decades of little or no progress, biomedical researchers are finally making some headway at detecting and treating sepsis, a deadly medical complication that sends a surge of pathogenic infection through the body and remains a major public health problem.

Study changes guidelines for sepsis management
University of Arizona Health Sciences researcher ends debate among physicians regarding sepsis management.

Improving outcomes for sepsis patients
More than 1 million sepsis survivors are discharged annually from acute care hospitals in the United States.

Genes linked to death from sepsis ID'd in mice
Bacteria in the bloodstream can trigger an overwhelming immune response that causes sepsis.

Read More: Sepsis News and Sepsis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.